Evidence map›Paper›PMID 26880493›Full record

ArticleScientific reports2016

Diagnosis of adults Xp11.2 translocation renal cell carcinoma by immunohistochemistry and FISH assays: clinicopathological data from ethnic Chinese population.

Yuanyuan Qu, Chengyuan Gu, Hongkai Wang, Kun Chang, Xiaoqun Yang, Xiaoyan Zhou, Bo Dai, Yao Zhu, Guohai Shi, Hailiang Zhang and 1 more

Open access · goldAbstract readEvaluation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
2.8field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Contrast-Enhanced Ultrasound Features of Adult Xp11.2 Translocation Renal Cell Carcinoma: Differential Diagnosis With Three Main Renal Cell Carcinoma Subtypes.Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine · 2022
    Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Yuanyuan QuDepartment of Urology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Chengyuan GuDepartment of Urology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Hongkai WangDepartment of Urology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Kun ChangDepartment of Urology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Xiaoqun YangDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.
Xiaoyan ZhouDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.
Bo DaiDepartment of Urology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Yao ZhuDepartment of Urology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Guohai ShiDepartment of Urology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Hailiang ZhangDepartment of Urology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Dingwei YeDepartment of Urology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Fudan University Shanghai Cancer Center · CNShanghai Medical College of Fudan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study aimed to assess the utility of transcription factor E3 (TFE3) break-apart fluorescence in situ hybridization (FISH) assay in diagnosis of Xp11.2 translocation renal cell carcinoma (Xp11.2 RCC) and to compare the clinicopathological features between adult Xp11.2 RCC and non-Xp11.2 RCC. 76 pathologically suspected Xp11.2 RCCs were recruited from our institution. Both TFE3 immunohistochemistry (IHC) and TFE3 FISH assay were performed for the entire cohort. The progression-free survival (PFS) and overall survival (OS) curves were estimated using the Kaplan-Meier method. FISH analysis confirmed 30 Xp11.2 RCCs, including 28 cases with positive TFE3 immunostaining and 2 cases with negative immunostaining. The false-positive and false-negative rates were 6.7% (2/30) and 4.3% (2/46), respectively, for TFE3 IHC compared with FISH assay. Xp11.2 RCC was significantly associated with higher pathological stage and Fuhrman nuclear grade compared with non-Xp11.2 RCC (P < 0.05). The median PFS and OS for TFE3 FISH-positive group were 13.0 months (95% CI, 8.4-17.6 months) and 50.0 months (95% CI, 27.6-72.4 months), respectively, while the median PFS and OS had not been reached for TFE3 FISH-negative group. In conclusion, TFE3 break-apart FISH assay is a highly useful and standard diagnostic method for Xp11.2 RCC. Adult Xp11.2 RCC is clinically aggressive and often presents at advanced stage with poor prognosis.

Indexed as

Chromosomes, Human, XIn Situ Hybridization, FluorescenceTranslocation, GeneticAdolescentAdultAgedAsian PeopleBasic Helix-Loop-Helix Leucine Zipper Transcription FactorsCarcinoma, Renal CellDiagnostic ErrorsFemaleHumansImmunohistochemistryMaleMiddle AgedSurvival AnalysisBasic Helix-Loop-Helix Leucine Zipper Transcription FactorsTFE3 protein, human

Identifiers

PMID26880493
PMCPMC4754949
OpenAlexW2275876064

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.